download

 

BioKinetic Europe have been working with Microsoft on the Windows 7 Ignite Program, allowing us access early to the Windows 7 Operating System. For more information about this please click on the following link and read the Case Study. http://www.microsoft.com/casestudies/Case_Study_Detail.aspx?casestudyid=4000004591

 

BioKinetic is delighted to announce receipt of MHRA (UK Regulatory Body) Phase I Standard & Supplementary Accreditation Status in July 2009.   We successfully completed MHRA GCP and GMP Inspections in April 2009. Assessment for Phase I Standard & Supplementary Accreditation was conducted at the same time.  The voluntary UK Accreditation Scheme for Phase I Clinical Trials Units is valid for a period of two years after which re-inspection is required. The remit of the inspections is GCP compliance and volunteer safety.  Those units awarded Supplementary Accreditation have been assessed for the stringent systems required for the conduct of trials involving compounds at all levels of risk including First in Man (FIM) and those that require review of risk factors by the MHRA's Clinical Trials Expert Advisory Group (EAG). This accreditation is testament to the quality service BioKinetic offers and we are delighted to have had our GCP and safety systems accredited by the UK MHRA.

 

BioKinetic Europe and Pharma Services Network work together to demonstrate the benefits of working with a UK CRO to American Pharma

 

BioKinetic Europe have successfully completed both the MHRA GCP and GMP Inspections April 2009